FUSEN PHARM (01652) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results and Evaluate Final Dividend

Bulletin Express

Mar 19

Fusen Pharmaceutical Company Limited (FUSEN PHARM, 01652) has scheduled a board meeting for 31 March 2026 in Hong Kong.

The agenda includes: 1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025. 2. Authorising the publication of the FY 2025 results announcement. 3. Considering the declaration of a final dividend, if any.

Board composition at the time of the announcement (19 March 2026) remains unchanged: Chairman and Executive Director Cao Zhiming, Executive Directors Hou Taisheng, Chi Yongsheng, and Meng Qingfen, alongside Independent Non-Executive Directors Lee Kwok Tung Louis, Dr. To Kit Wa, and Yu Ho Ming.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1124465505"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124465505\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124465505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124465505","market":"hk","top_or_hot":-1,"title":"FUSEN PHARM (01652) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results and Evaluate Final Dividend","media":"Bulletin Express","content":"<p>Fusen Pharmaceutical Company Limited (FUSEN PHARM, 01652) has scheduled a board meeting for 31 March 2026 in Hong Kong.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Authorising the publication of the FY 2025 results announcement.  \n3. Considering the declaration of a final dividend, if any.</p>\n<p>Board composition at the time of the announcement (19 March 2026) remains unchanged: Chairman and Executive Director Cao Zhiming, Executive Directors Hou Taisheng, Chi Yongsheng, and Meng Qingfen, alongside Independent Non-Executive Directors Lee Kwok Tung Louis, Dr. To Kit Wa, and Yu Ho Ming.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FUSEN PHARM (01652) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results and Evaluate Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFUSEN PHARM (01652) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results and Evaluate Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-19 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fusen Pharmaceutical Company Limited (FUSEN PHARM, 01652) has scheduled a board meeting for 31 March 2026 in Hong Kong.</p>\n<p>The agenda includes:  \n1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Authorising the publication of the FY 2025 results announcement.  \n3. Considering the declaration of a final dividend, if any.</p>\n<p>Board composition at the time of the announcement (19 March 2026) remains unchanged: Chairman and Executive Director Cao Zhiming, Executive Directors Hou Taisheng, Chi Yongsheng, and Meng Qingfen, alongside Independent Non-Executive Directors Lee Kwok Tung Louis, Dr. To Kit Wa, and Yu Ho Ming.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"","article_id":"1124465505","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124465505","pubTimestamp":1773923039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fusen Pharmaceutical Company Limited (FUSEN PHARM, 01652) has scheduled a board meeting for 31 March 2026 in Hong Kong. The agenda includes:   1. Reviewing and approving the consolidated annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业"},"translate_title":"富森药业(01652)定于2026年3月31日召开董事会批准2025财年业绩并评估末期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"Fusen Pharmaceutical Company Limited (FUSEN PHARM, 01652) has scheduled a board meeting for 31 March 2026 in Hong Kong.\nThe agenda includes:  \n1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Authorising the publication of the FY 2025 results announcement.  \n3. Considering the declaration of a final dividend, if any.\nBoard composition at the time of the announcement (19 March 2026) remains unchanged: Chairman and Executive Director Cao Zhiming, Executive Directors Hou Taisheng, Chi Yongsheng, and Meng Qingfen, alongside Independent Non-Executive Directors Lee Kwok Tung Louis, Dr. To Kit Wa, and Yu Ho Ming.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}